Clinicopathological features and prognosis of omental gastrointestinal stromal tumor: evaluation of a pooled case series

Feng, Fan; Tian, Yangzi; Liu, Zhen; Liu, Shushang; Xu, Guanghui; Guo, Man; Lian, Xiao; Fan, Daiming; Zhang, Hongwei

doi:10.1038/srep30748

Cited by 6 publications

(12 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median tumor size was 9.0 cm (range: 2.6-30.0 cm) and the median mitotic rate was 5.0/50HPF. In this study, the main clinical presentations were abdominal mass in 14 cases, abdominal distention and pain in 6, detected by healthy screening in one, spontaneous rupture of tumor and intra-abdominal hemorrhage in one, and synchrous liver metastasis was in one case at the time of diagnosis, which is similar to the literature report [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Also, our study revealed that the tumor size was 6.8cm (ranging from 4.0cm to 22.0cm), including 2 cases with tumor <5cm in diameter, 6 with tumor size between 5 to 10cm, 14 with tumor> 10cm, this results suggested the most EGISTs were very advanced disease at diagnosis, difficult to diagnose in early stage.…”

Section: Discussionsupporting

confidence: 86%

“…In 95% of EGIST cases, the CD117 protein exhibits a strong, diffuse positive immunohistochemical reaction, and 60-70% of EGISTs were CD34-positive [2][3][4]. Feng et al [12] reported the positive rates of CD117, CD34 and DOG-1 were 84.5%, 83.7% and 88.9%, respectively. An immunochemical study of EGIST from Reith et al [9], revealed that the tumors expressed CD117 (100%), CD34 (50%), NSE (44%), SMA (26%), desmin (4%), and S-100 protein (4%).…”

Section: Histopathological Behaviormentioning

confidence: 99%

“…The estimated 5-and 15-year recurrence-free survival rates for GISTs treated with surgery alone are 70.5 and 59.9%, respectively [2,[4][5][6][7][8][9]. Feng et al [12]summarized 93 cases of omental GISTs, the 1-, 3-and 5-year disease-free survival was 90.8%, 86.3% and 86.3%, respectively. Miettinen et al [10] reported the median survival was 129 months (range: 0 to 397 months).…”

Section: Survival and Recurrencementioning

confidence: 99%

“…Tumors that originate from outside of the gastrointestinal tract, which show no connection to the wall or the peritoneal surface of the gastrointestinal tract, are defined as extra-gastrointestinal stromal tumor (EGIST) [5]. It is reported that EGISTs constitute only 5%-10% of GISTs cases, and most EGISTs are derived from the mesentery, omentum, and retroperitoneum [4][5][6][7][8][9][10], and other unusual primary anatomic locations of EGISTs have also been reported, including the liver, pancreas, mediastinum and gall bladder [5][6][7][8][9][10][11][12][13][14][15]. Though EGISTs exhibit similar histological features and immunohistochemistry to GISTs, they are a unique entity, which require distinction from GISTs [11].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diagnosis and Treatment of Abdominal Extra- Gastrointestinal Stromal Tumors

Rao

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: To investigate the clinicopathological features and treatment outcome of abdominal extra-gastrointestinal stromal tumors (EGISTs). Methods: The clinicopathological data and follow-up results of 22 patients with abdominal EGISTs proved by pathology were reviewed retrospectively. Results: The main symptoms were abdominal mass in 14 cases, abdominal distention and pain in 6, detected by healthy screening in one, spontaneous rupture of tumor and intra-abdominal hemorrhage in one. The tumor locations were retroperitonum in 11 cases, mesentery in 6, and greater momentum in 3, liver in one and pancreas in one, and the tumor size<5cm in one case, 5-10cm in 9 and >10cm in 12. The immunochemistry stain revealed that the positive rate of CD117 was 95.5%, CD34 36.4%, DOG-1 13.6%, SMA 4.5%, and S-100 protein 4.5%. The resection rate was 81.8% (18/22 cases), including tumor resection in 16, an irregular hepatectomy in one, a distal pancreactomy in one, and simple laparotomy with biopsy in 4. The radicality of operation was R0 resection in 14 cases, R1 resection in 2 and R2 resection in 2. Eleven cases (50.0%) in this group received imatinib adjuvant treatment, including administration greater than 1 year in 6 cases, and greater than 3 years in 5. The 1, 3, 5-year overall survival rates in the study were 88.9% (16/18 cases), 72.2% (13/18), and 55.6% (10/21), respectively. Among them, 72.7% (8/11), 45.5% (5/11) and 45.5% (5/11) were for retroperitoneal tumors, respectively; and 100.0% (6/6), 100.0% (6/6) and 66.7% (4/6) for mesentery EGIST, respectively. Conclusions: Abdominal EGISTs have a high potential of malignancy, the surgery is the choice of the treatment, and the postoperative adjuvant treatment with imatinib may improve the survival rate of high-risk cases. [Key words] Extra-gastrointestinal stromal tumor; Abdomen; Surgical treatment; Imatinib

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Histopathological Behaviormentioning

confidence: 99%

Section: Survival and Recurrencementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnosis and Treatment of Abdominal Extra- Gastrointestinal Stromal Tumors

Rao

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…It is considered to originate from interstitial cells of Cajal, the pacemaker cells of GI tract [2]. Histologically, the most common cell morphology was spindle, followed by epithelioid and mixed phenotype [3].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Features and Prognosis of Gastrointestinal Stromal Tumor Located in the Jejunum and Ileum

Feng

Wang

et al. 2018

Dig Surg

Self Cite

View full text Add to dashboard Cite

Background: Data about the clinicopathological features and prognosis of gastrointestinal stromal tumors (GISTs) located in jejunum and ileum are lacking. The present study aims to investigate the features and prognosis of jejunal and ileal GISTs based on the Surveillance, Epidemiology, and End Results (SEER) database. Patients and Methods: Cases of jejunal and ileal GISTs were extracted from SEER database. Clinicopathological characteristics and survival data of patients were recorded. The clinicopathological features and prognosis of patients were analyzed. Results: There were 399 male (56.8%) and 303 female (43.2%). The median age was 60 years (17–96). Four hundred and seventy-two tumors were located in the jejunum (67.2%) and 230 tumors in the ileum (32.8%). The median tumor size was 7.0 cm (0.5–90). The 5-, 10-, and 20-year disease specific survival (DSS) was 84.4, 71.2, and 54.2% respectively. Clinicopathological features were comparable between tumors located in the jejunum and ileum (all p > 0.05) except gender and tumor size (both p < 0.05). Jejunal GISTs, rather than ileal GISTs (p = 0.043), were commonly found in the males. The tumor size of jejunal GISTs was smaller than that of ileal GISTs (p = 0.010). The DSS of jejunal GISTs was comparable to that of ileal GISTs (p = 0.269). Conclusions: Jejunal GISTs were more common than ileal GISTs. The prognosis was comparable between jejunal and ileal GISTs.

show abstract